<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Myeloproliferative neoplasms (MPN)</td> </tr> <tr> <td class="indent1">Chronic myeloid leukemia (CML), <em>BCR-ABL1<sup>+</sup></em></td> </tr> <tr> <td class="indent1">Chronic neutrophilic leukemia (CNL)</td> </tr> <tr> <td class="indent1">Polycythemia vera (PV)</td> </tr> <tr> <td class="indent1">Primary myelofibrosis (PMF)</td> </tr> <tr> <td class="indent2"> <ul> <li>PMF, prefibrotic/early stage</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>PMF, overt fibrotic stage</li> </ul> </td> </tr> <tr> <td class="indent1">Essential thrombocythemia (ET)</td> </tr> <tr> <td class="indent1">Chronic eosinophilic leukemia, not otherwise specified (NOS)</td> </tr> <tr class="divider_bottom"> <td class="indent1">MPN, unclassifiable</td> </tr> <tr> <td class="subtitle1_single">Mastocytosis</td> </tr> <tr> <td class="subtitle1_single">Myeloid/Lymphoid neoplasms with eosinophilia and rearrangement of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em>, or with <em>PCM1-JAK2</em></td> </tr> <tr> <td class="indent1">Myeloid/Lymphoid neoplasms with <em>PDGFRA</em> rearrangement</td> </tr> <tr> <td class="indent1">Myeloid/Lymphoid neoplasms with <em>PDGFRB</em> rearrangement</td> </tr> <tr class="divider_bottom"> <td class="indent1">Myeloid/Lymphoid neoplasms with <em>FGFR1</em> rearrangement</td> </tr> <tr> <td class="subtitle1_single">Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)</td> </tr> <tr> <td class="indent1">Chronic myelomonocytic leukemia (CMML)</td> </tr> <tr> <td class="indent1">Atypical chronic myeloid leukemia (aCML), BCR-ABL1<sup>â€“</sup></td> </tr> <tr> <td class="indent1">Juvenile myelomonocytic leukemia (JMML)</td> </tr> <tr> <td class="indent1">MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</td> </tr> <tr class="divider_bottom"> <td class="indent1">MDS/MPN, unclassifiable</td> </tr> <tr> <td class="subtitle1_single">Myelodysplastic syndromes (MDS)</td> </tr> <tr> <td class="indent1">MDS with single lineage dysplasia</td> </tr> <tr> <td class="indent1">MDS with ring sideroblasts (MDS-RS)</td> </tr> <tr> <td class="indent2"> <ul> <li>MDS-RS and single lineage dysplasia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>MDS-RS and multilineage dysplasia</li> </ul> </td> </tr> <tr> <td class="indent1">MDS with multilineage dysplasia</td> </tr> <tr> <td class="indent1">MDS with excess blasts</td> </tr> <tr> <td class="indent1">MDS with isolated del(5q)</td> </tr> <tr class="divider_bottom"> <td class="indent1">MDS, unclassifiable</td> </tr> <tr> <td class="subtitle1_single">Myeloid neoplasms with germ line predisposition</td> </tr> <tr> <td class="subtitle1_single">Acute myeloid leukemia (AML) and related neoplasms</td> </tr> <tr> <td class="indent1">AML with recurrent genetic abnormalities</td> </tr> <tr> <td class="indent2"> <ul> <li>AML with t(8;21)(q22;q22.1);<em>RUNX1-RUNX1T1</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);<em>CBFB-MYH11</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>APL with <em>PML-RARA</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with t(9;11)(p21.3;q23.3);<em>MLLT3-KMT2A</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with t(6;9)(p23;q34.1);<em>DEK-NUP214</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2</em>, <em>MECOM</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);<em>RBM15-MKL1</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with mutated <em>NPM1</em></li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with biallelic mutations of <em>CEBPA</em></li> </ul> </td> </tr> <tr> <td class="indent1">AML with myelodysplasia-related changes</td> </tr> <tr> <td class="indent1">Therapy-related myeloid neoplasms</td> </tr> <tr> <td class="indent1">AML, NOS</td> </tr> <tr> <td class="indent2"> <ul> <li>AML with minimal differentiation</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML without maturation</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>AML with maturation</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Acute myelomonocytic leukemia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Acute monoblastic/monocytic leukemia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Pure erythroid leukemia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Acute megakaryoblastic leukemia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Acute basophilic leukemia</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Acute panmyelosis with myelofibrosis</li> </ul> </td> </tr> <tr> <td class="indent1">Myeloid sarcoma</td> </tr> <tr> <td class="indent1">Myeloid proliferations related to Down syndrome</td> </tr> <tr> <td class="indent2"> <ul> <li>Transient abnormal myelopoiesis (TAM)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2"> <ul> <li>Myeloid leukemia associated with Down syndrome</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Blastic plasmacytoid dendritic cell neoplasm</td> </tr> <tr> <td class="subtitle1_single">Acute leukemias of ambiguous lineage</td> </tr> <tr> <td class="indent1">Acute undifferentiated leukemia</td> </tr> <tr> <td class="indent1">Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);<em>BCR-ABL1</em></td> </tr> <tr> <td class="indent1">MPAL with t(v;11q23.3); <em>KMT2A</em> rearranged</td> </tr> <tr> <td class="indent1">MPAL, B/myeloid, NOS</td> </tr> <tr class="divider_bottom"> <td class="indent1">MPAL, T/myeloid, NOS</td> </tr> <tr> <td class="subtitle1_single">B-lymphoblastic leukemia/lymphoma</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma, NOS</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);<em>BCR-ABL1</em></td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); <em>KMT2A</em> rearranged</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);<em>ETV6-RUNX1</em></td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with hyperdiploidy</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with hypodiploidy</td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) <em>IL3-IGH</em></td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);<em>TCF3-PBX1</em></td> </tr> <tr> <td class="indent1">B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like*</td> </tr> <tr class="divider_bottom"> <td class="indent1">B-lymphoblastic leukemia/lymphoma with iAMP21*</td> </tr> <tr> <td class="subtitle1_single" style="border-bottom: medium none;">T-lymphoblastic leukemia/lymphoma</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Provisional entity.</div><div class="graphic_reference">Modified with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright Â© 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 110239 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
